Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CLIGFOTCMKTS:NHNKYOTCMKTS:UDHCFOTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLIGFClinigen Group$8.02$8.02$8.02▼$11.56$1.07B0.498,620 shsN/ANHNKYNihon Kohden$12.02-7.6%$12.31$9.86▼$20.00$2.22B0.325,781 shs4,024 shsUDHCFUDG Healthcare$14.79$14.79$10.86▼$14.79$3.68B0.6216,957 shsN/AZLDPFZealand Pharma A/S$67.62-2.4%$66.33$57.97▼$141.74$4.80B0.92914 shs252 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLIGFClinigen Group0.00%0.00%0.00%0.00%0.00%NHNKYNihon Kohden-7.58%-0.37%-3.88%-14.36%-16.45%UDHCFUDG Healthcare0.00%0.00%0.00%0.00%0.00%ZLDPFZealand Pharma A/S0.00%+8.48%+1.02%-30.84%-24.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLIGFClinigen GroupN/AN/AN/AN/AN/AN/AN/AN/ANHNKYNihon Kohden1.8305 of 5 stars0.05.01.70.02.20.01.3UDHCFUDG HealthcareN/AN/AN/AN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLIGFClinigen Group 0.00N/AN/AN/ANHNKYNihon Kohden 0.00N/AN/AN/AUDHCFUDG Healthcare 0.00N/AN/AN/AZLDPFZealand Pharma A/S 3.67Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest NHNKY, ZLDPF, CLIGF, and UDHCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025ZLDPFZealand Pharma A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLIGFClinigen Group$704.71M1.51$1.43 per share5.60$4.52 per share1.77NHNKYNihon Kohden$1.54B1.34$0.52 per share23.30$7.08 per share1.70UDHCFUDG Healthcare$1.28B2.87$0.74 per share19.91$3.95 per share3.74ZLDPFZealand Pharma A/S$9.09M528.37N/AN/A$4.49 per share15.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLIGFClinigen Group$40.78MN/A0.00∞N/AN/AN/AN/AN/ANHNKYNihon Kohden$117.48M$0.5617.67∞N/A7.71%15.08%11.98%7/31/2025 (Estimated)UDHCFUDG Healthcare$92.83MN/A0.00∞N/AN/AN/AN/AN/AZLDPFZealand Pharma A/S-$102.18M-$2.49N/AN/AN/A-1,725.03%-15.24%-13.77%N/ALatest NHNKY, ZLDPF, CLIGF, and UDHCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q4 2025NHNKYNihon KohdenN/A$0.18N/A$0.24N/A$439.11 million5/8/2025Q1 2025ZLDPFZealand Pharma A/S-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLIGFClinigen GroupN/AN/AN/AN/AN/ANHNKYNihon Kohden$0.110.92%N/A19.64%N/AUDHCFUDG Healthcare$0.191.28%N/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLIGFClinigen GroupN/AN/AN/ANHNKYNihon KohdenN/A4.192.79UDHCFUDG Healthcare0.351.901.81ZLDPFZealand Pharma A/S0.0335.4935.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLIGFClinigen GroupN/ANHNKYNihon Kohden0.10%UDHCFUDG HealthcareN/AZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipCLIGFClinigen GroupN/ANHNKYNihon KohdenN/AUDHCFUDG HealthcareN/AZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLIGFClinigen Group1,069133.03 millionN/ANot OptionableNHNKYNihon Kohden5,891170.96 millionN/ANot OptionableUDHCFUDG Healthcare9,000248.71 millionN/ANot OptionableZLDPFZealand Pharma A/S34071.02 millionN/ANot OptionableNHNKY, ZLDPF, CLIGF, and UDHCF HeadlinesRecent News About These CompaniesCantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2025 EarningsMay 24, 2025 | marketbeat.comZealand CEO: Oral weight loss meds are not the future for treating obesityMay 15, 2025 | seekingalpha.comZealand Pharma A/S (ZLDPF) Projected to Post Quarterly Earnings on ThursdayMay 10, 2025 | marketbeat.comZealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...May 9, 2025 | finance.yahoo.comInside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambitMay 2, 2025 | cnbc.comZealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?May 1, 2025 | zacks.comZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as Chief Scientific OfficerApril 23, 2025 | contractpharma.comZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comZealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025April 19, 2025 | finance.yahoo.comZealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With RocheApril 11, 2025 | wsj.comGubra’s obesity drug trial success weighs on Zealand Pharma stockApril 2, 2025 | investing.comZealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)March 18, 2025 | markets.businessinsider.comRoche-Zealand deal is the latest to boost obesity spaceMarch 12, 2025 | msn.comZealand Pharma's new drug petrelintide will help people lose weight: CEOMarch 12, 2025 | youtube.comRoche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidateMarch 12, 2025 | cnbc.comRoche Agrees to Develop Weight-Loss Therapy With Zealand PharmaMarch 12, 2025 | msn.comRoche to develop, commercialize obesity drug with Zealand PharmaMarch 12, 2025 | reuters.comMedia Sentiment Over TimeNHNKY, ZLDPF, CLIGF, and UDHCF Company DescriptionsClinigen Group OTCMKTS:CLIGF$8.02 0.00 (0.00%) As of 03/24/2023Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Nihon Kohden OTCMKTS:NHNKY$12.02 -0.99 (-7.58%) As of 05/29/2025 02:22 PM EasternNihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.UDG Healthcare OTCMKTS:UDHCF$14.79 0.00 (0.00%) As of 11/29/2021UDG Healthcare Plc engages in the supply and distribution of pharmaceutical and medical products. It operates through the following segments: Ashfield, Sharp, and Aquilant. The Ashfield segment provides commercialization services for the pharmaceutical and healthcare industry. The Sharp segment offers contract packaging and clinical trial packaging services. The Aquilant segment involves. outsourced sales, marketing, distribution, and engineering services to the medical and scientific sectors. The company was founded in 1948 and is headquartered in Dublin, Ireland.Zealand Pharma A/S OTCMKTS:ZLDPF$67.62 -1.70 (-2.45%) As of 05/28/2025 01:34 PM EasternZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
